白藜芦醇后处理对大鼠心肌缺血/再灌注损伤的保护作用及机制研究

doi:10.3969/j.issn.1002-1949.2018.10.016

摘要
图/表
参考文献(13)
相关文章 (4)

全文: PDF (910 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察白藜芦醇后处理对SD大鼠的心肌缺血/再灌注(I/R)损伤的保护作用并探讨其机制。方法选用80只SD雄性大鼠，随机分为假手术组、I/R组、I/R+白藜芦醇(20 mg/kg)组和I/R+白藜芦醇+LY294002(5 mg/kg)组。采用结扎SD大鼠左冠状动脉的前降支30 min，再灌注2 h的方法构建心肌I/R损伤模型，在再灌注前1 min由舌下静脉推注白藜芦醇或LY294002。首先TTC法检测各组心肌组织的梗死面积；检测各组大鼠血浆和心肌组织中丙二醛（MDA）和超氧化物歧化酶（SOD）含量以及心肌组织中血红素加氧酶-1（heme oxygenase-1, HO-1）的含量，最后用Western blot法检测心肌组织中的PI3K、p-Akt、Nrf2、HO-1蛋白表达变化水平。结果与I/R组比较，白藜芦醇后处理可明显降低心肌梗死面积，也可降低血浆中MDA含量，升高SOD活性水平，可增强HO-1活性（P<0.05），进一步显示白藜芦醇增加了I/R大鼠心肌组织中PI3K、p-Akt、Nrf2、HO-1蛋白的表达水平（P<0.05），其作用又可被PI3K/Akt抑制剂LY294002部分消除。结论白藜芦醇后处理对I/R后的心肌组织有保护作用，其机制可能与白藜芦醇上调PI3K/Akt/Nfr2的活性，进而增强HO-1蛋白的活性和表达，从而发挥其抗氧化作用有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李丹
	何菲
	庞科

关键词 ：白藜芦醇, 后处理, 缺血/再灌注（I/R）, 血红素加氧酶-1(HO-1), PI3K/Akt/Nfr2

基金资助:重庆市永川区科委软科学研究项目（ycstc,2014rc9004）

通讯作者: 何菲（1980-），男，硕士，讲师，E-mail：9881226@qq.com。

作者简介: 李丹（1980-），男，硕士，主治医师。

引用本文:

李丹，何菲，庞科. 白藜芦醇后处理对大鼠心肌缺血/再灌注损伤的保护作用及机制研究[J]. 中国急救医学, 2018, 38(10): 910-914.
Li Dan, He Fei, Pang Ke. Protective effect of resveratrol post-treament on myocardial ischemia/reperfusion injury of the rats. Chinese Journal of Critical Care Medicine, 2018, 38(10): 910-914.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2018.10.016 或 http://www.cnemergency.org.cn/CN/Y2018/V38/I10/910

［1］Cuadrado A, Rojo AI. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections［J］. Curr Pharm Des, 2008, 14(5): 429-442. ［2］Buhrmann C, Popper B, Aggarwal BB, et al. Resveratrol downregualtes inflammatory pathway activated by lymphotoxin α (TNF-α) in articular chondrocytes: comparison with TNF-α［J］. PLoS One, 2017, 12(11): e0 186 993. ［3］RegeSD, Kumar S, Wilson DN et al. Resveratrol protects the brain of obese mice from oxidative damage［J］. Oxid Med Cell Longev, 2013, 2013: 419 092. ［4］Kimura Y, Sumiyoshi M. Resveratrol prevents tumor growth and metastasis by inhibiting lymphangiogenesis and M2 macrophage activation and differentiation in tumor-associated macrophages［J］. Nutr Cancer, 2016, 68(4): 667-678. ［5］Chen ML, Yi L, Zhang Y, et al. Resveratrol attenuates Trimethylamine-N-Oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota［J］. MBio, 2016, 7(2): e02210-e02215 ［6］Yang L, Zhang Y, Zhu M, et al. Resveratrol attenuates myocardial ischemia/reperfusion injury through up-regulation of vascular endothelia growth factor B［J］. Free Radic Biol Med, 2016, 101: 1-9. ［7］Yang H, Zhang A, Zhang Y, et al. Resveratrol pretreatment protected against cerebral ischemia/reperfusion injury in rats via expansion of T regulatory cells ［J］. J Stroke Cerebrovasc Dis, 2016, 25(8): 1914-1921. ［8］Shimizu K, Miyagi S, Miyazawa K, et al. Resveratrol prevents warm ischemia-reperfusion injury in liver grafts from non-heart-beating donor rats［J］. Transplant Proc, 2016, 48(4): 1221-1225. ［9］Zheng H, Guo H, Hong Y, et al. The effects of age and resveratrol on the hypoxic preconditioning protection against hypoxia-reperfusion injury: studies in rat hearts and human cardiomyocytes［J］. Eur J Cardiothorac Surg, 2015, 48(3): 375-381. ［10］Ren J, Fan C, Chen N, et al. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats［J］. Neurochem Res, 2011, 36(12): 2352-2362. ［11］Cheng XY, Gu XY, Gao Q, et al. Effects of dexmedetomidine postconditioning on myocardial ischemia and the role of the PI3K/Akt-dependent signaling pathway in reperfusion injury［J］. Mol Med Rep, 2016, 14(1): 797-803. ［12］He D, Liu X, Pang Y, et al. Inhibitory effect of resveratrol on ischemia reperfusion-induced cardiocyte apoptosis and its relationship with PI3K-Akt signaling pathway［J］. Zhongguo Zhong Yao Za Zhi, 2012, 37(15): 2323-2326. ［13］Jang HJ, Hong EM, Kim M, et al. Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer［J］. Oncotarget, 2016, 7(29): 46 219-46 229.